Endometriosis is a chronic condition affecting approximately 10% of women. It is frequently associated with persistent or recurrent pelvic and abdominal pain. The mechanisms underlying pain in endometriosis are complex and may include direct stimulation from endometriotic lesions and local inflammation, nerve involvement, and alterations in central pain processing. In some individuals, sensitization of the nervous system may result in pain persisting despite limited ongoing tissue injury.
Surgery is an important treatment option for patients whose symptoms are insufficiently controlled by medical therapy or in whom surgery is indicated to improve fertility. The primary aim of surgery is to remove endometriosis lesions, thereby reducing symptoms and improving quality of life.
However, patients undergoing surgery for endometriosis often experience more severe postoperative pain and require greater opioid consumption than patients undergoing other gynecological procedures. They may also be at increased risk of developing persistent postoperative pain, defined as pain that continues beyond the expected healing period and persists for months after surgery.
Esketamine is a well-established medication used in anesthesia and pain management. Its pharmacological effects and safety profile are well characterized. It is commonly administered in patients with pre-existing pain conditions or chronic opioid use. Previous studies suggest that esketamine may reduce acute postoperative pain, decrease opioid requirements, and provide benefits in certain neuropathic and chronic pain conditions. However, its efficacy and safety have not been systematically evaluated in patients undergoing surgery for endometriosis.
The ENDPAIN trial aims to evaluate the efficacy and safety of perioperative esketamine in patients undergoing surgery for endometriosis, with the goal of improving postoperative pain management and recovery.
Primary Objective: To evaluate the efficacy and safety of perioperative esketamine in reducing postoperative pain in patients undergoing intra-abdominal surgery for endometriosis.
Secondary Objectives: To collect information on preoperative and postoperative pain in patients undergoing surgery for endometriosis in order to improve understanding of the mechanisms and risk factors associated with severe acute postoperative pain and persistent postoperative pain.
To collect information on the effects of other analgesic medications used as part of routine clinical care in participating centres and to explore potential interactions between these medications and esketamine.
Primary Endpoint: Postoperative pain measured using a Numerical Rating Scale (NRS) at 30 minutes, and at 6, 12, 24, and 48 hours after surgery.
Secondary Endpoints:
Hospital-free days within 30 days after surgery, defined as the number of days spent alive and outside an acute-care hospital during the first 30 postoperative days.
Opioid consumption during the first 48 postoperative hours. Quality of Recovery (QoR-15) score. Serious adverse events. Adverse reactions associated with esketamine, including hypertension, tachycardia, hallucinations or dissociative symptoms, sedation, nausea, and vomiting.
Persistent postoperative pain and other patient-reported outcomes assessed three months after surgery.
Trial Design: The ENDPAIN trial is a triple-blinded, randomized, placebo-controlled clinical trial with a follow-up duration of three months.
Participants will be enrolled on the day of surgery. Most study data will be collected during the first 48 postoperative hours. A follow-up assessment will be conducted three months after surgery and may take place either during a study visit or by telephone, according to participant preference and local site procedures.
Trial Population: Adult patients undergoing elective surgery for endometriosis will be eligible for inclusion.
Patients will be excluded if they:
Do not provide informed consent. Have a known hypersensitivity or allergy to esketamine. Have a current or previous history of ketamine or esketamine misuse. Have a medical condition in which esketamine is contraindicated, such as elevated intracranial or intraocular pressure.
Have severe systemic disease (ASA Physical Status > III). Have severe psychiatric illness. Intervention: Participants will be randomly assigned in a 1:1 ratio to one of two treatment groups. Participants allocated to the intervention group will receive esketamine 0.5 mg/kg following induction of anesthesia, followed by a continuous infusion of 0.15 mg/kg/hour until approximately 20 minutes before skin closure. Participants allocated to the control group will receive an equivalent volume of placebo consisting of sodium chloride solution (saline).

Start Date01 Jan 2028

Sponsor / Collaborator

Region Skåne Holding AB

[+4]

NCT07888933

/ Not yet recruitingPhase 2IIT

Intravenous Ketamine for the Management of Acute Suicidal Crisis: Effect on Psychiatric Hospital Length of Stay - A Randomized, Double-Blind, Active Placebo-Controlled Superiority Trial

This randomized, double-blind, active placebo-controlled superiority trial will evaluate whether intravenous esketamine reduces time to psychiatric hospital discharge in adults hospitalized because of acute suicide risk. A total of 106 participants will be randomized in a 1:1 ratio to receive intravenous esketamine or midazolam as an active placebo. Participants assigned to esketamine will receive eight 40-minute intravenous infusions at a dose of 0.5 mg/kg administered twice weekly. The primary outcome is time from the first study infusion to psychiatric hospital discharge. Secondary outcomes include suicidal ideation and behavior, depressive symptoms, psychological pain, hopelessness, global clinical improvement, safety, tolerability, dissociative symptoms, and healthcare costs. Exploratory analyses will investigate peripheral inflammatory markers, BDNF, and polygenic risk scores as potential predictors or mediators of treatment response. Clinical follow-up will continue through Week 12.

Start Date30 Apr 2027

Sponsor / Collaborator

University of Sao Paulo

ChiCTR2600135771

/ Not yet recruitingNot ApplicableIIT

Effects of esketamine and dexmedetomidine on postoperative sleep quality and its electroencephalographic mechanisms in thoracic surgery patients: a three-arm randomized controlled trial

Start Date01 Dec 2026

Sponsor / Collaborator

The First Affiliated Hospital of Zhengzhou University

100 Clinical Results associated with Esketamine Hydrochloride

100 Translational Medicine associated with Esketamine Hydrochloride

100 Patents (Medical) associated with Esketamine Hydrochloride

2,852

Literatures (Medical) associated with Esketamine Hydrochloride

01 Jan 2027·JOURNAL OF AFFECTIVE DISORDERS

Feasibility and tolerability of virtual reality during esketamine treatment: A pilot study

Article

Author: Kumpf, Kristina T ; Baghaei, Nilufar ; Ansari, Mina ; Wilkinson, Samuel T ; Elliott, Thomas C ; Curran, Erin ; Nikayin, Sina

OBJECTIVE:

Ketamine/esketamine produce rapid antidepressant effects, with growing interest in how acute subjective experiences and the surrounding set and setting shape clinical outcomes. Little is known about how audiovisual adjustments during ketamine/esketamine treatment influence comfort, tolerability, or patient experience, despite their common use in clinical practice. Virtual reality (VR) is one immersive approach being explored in this context. This study examines the feasibility and tolerability of integrating VR into maintenance ketamine/esketamine sessions.

METHODS:

Study 1 surveyed patients receiving ketamine/esketamine regarding their dissociative experience and openness to integrating virtual reality into treatment. In study 2, patients receiving esketamine integrated VR into clinical treatment. Participants were trained in the use of a VR headset and completed one esketamine session with VR. The primary objective was to assess safety, tolerability, and feasibility.

RESULTS:

Participants from Study 1 highlighted auditory (33%, 7/21) and visual (52%, 11/21) discomfort as common challenges during ketamine treatment; the majority (71%, 15/21) expressed openness to integrating VR into clinical treatment. In Study 2, five patients integrated VR into a single treatment session, with one using it throughout the session. Participants who wore glasses had difficulty integrating VR and reported nausea. All participants showed decreased altered experience as measured by the 5-Dimensional Altered States of Consciousness scale.

CONCLUSIONS/RELEVANCE:

This pilot study examines factors affecting the feasibility and tolerability of VR during ketamine treatment and highlights considerations for future research. The observed reduction in 5D-ASC scores raises questions about whether VR dampens dissociative intensity, with potential clinical implications warranting further exploration.

01 Jan 2027·Brazilian Journal of Anesthesiology

Health-related quality of life after ketamine or esketamine treatment for chronic pain: a review of randomized controlled trials

Letter

Author: Garcia, Stefania Lacerda ; Araújo, Isabel Lima ; Figueiredo, Alexandre Vieira ; Kusterer, Liliane Else Falcão Lins ; Quarantini, Lucas de Castro

Chronic pain, lasting over three months, significantly impairs patients' health-related quality of life (HRQoL) due to its impact on physical, psychological, and social well being. Given the limitations and risks associated with opioid use, there is growing interest in alternative analgesics. Ketamine and its S-enantiomer, esketamine, as NMDA receptor antagonists, are becoming important treatments for central sensitization. However, evidence regarding their direct positive effect on HRQoL in chronic pain patients remains sparse. This systematic review was conducted following Cochrane standards and the PRISMA framework. The search included only randomized clinical trials (RCTs) in adult patients focusing on HRQoL measures following ketamine or esketamine treatment for chronic pain. Methodological bias was assessed using the Cochrane RoB2 tool. Results: The systematic search yielded five eligible RCTs involving 405 patients with diverse chronic pain conditions. The studies were mixed and heterogeneous due to various routes of administration and different HRQoL instruments. Two studies reported a significant improvement in HRQoL (for central pain/low back pain); two found no difference (oncological/neuropathic pain); and one reported a worsening of HRQoL in palliative care cancer patients, linked to adverse events. Conclusion: The significant heterogeneity across the selected RCTs (pain types, regimens, routes, and HRQoL tools) makes meta-analytic synthesis unfeasible. The results on the impact of ketamine and esketamine on HRQoL in chronic pain patients are inconsistent, ranging from improvement to worsening. Future research must prioritize HRQoL as a primary outcome and standardize protocols to establish stronger, generalizable evidence.

31 Dec 2026·ANNALS OF MEDICINE

Efficacy of esketamine in reducing nausea and vomiting after anesthesia: a systematic review and meta-analysis of randomized controlled trials

Review

Author: Qu, Shuangquan ; Wang, Jing ; Wu, Lei ; Tang, Ling ; Zhu, Yi ; Du, Zhen

BACKGROUND:

Postoperative nausea and vomiting (PONV) are significant perioperative challenges. This study evaluated the efficacy of perioperative esketamine in preventing PONV.

MATERIALS AND METHODS:

We systematically searched Embase, PubMed, Web of Science, and the Cochrane Library from inception to August 2025 for randomized controlled trials investigating the effect of perioperative esketamine on PONV. The primary outcome was PONV incidence. Secondary outcomes included time to first flatus, postoperative pain degree, anxiety scores, agitation, anesthesia recovery time, and post-anesthesia care unit (PACU) stay duration. Data were analyzed using RevMan 5.4 and STATA 15.0 software. Sensitivity and subgroup analyses were performed to assess result stability and explore potential sources of heterogeneity.

RESULTS:

Thirty-eight randomized trials (3,425 patients) were included. Esketamine reduced the risk of nausea (RR=0.69, 95% CI: 0.53-0.90) and vomiting (RR=0.75, 95% CI: 0.57-0.98), shortened time to first flatus (SMD=-0.81, 95% CI: -1.48 to -0.15), and decreased rescue analgesic needs within 2 days (SMD=0.32, 95% CI: 0.2-0.5). However, it prolonged anesthesia recovery time (SMD=0.97, 95% CI: 0.28-1.67) and PACU stay (SMD=0.76, 95% CI: 0.27-1.26).

CONCLUSIONS:

Perioperative esketamine may reduce PONV and aid gastrointestinal recovery, but its potential to delay anesthesia recovery and PACU discharge requires consideration. Further studies are needed to clarify its risk-benefit profile.

DATE OF FIRST SUBMISSION TO PROSPERO:

10 March 2024.

DATE OF THE START OF STUDY SCREENING AGAINST ELIGIBILITY CRITERIA:

21 March 2024.

525

News (Medical) associated with Esketamine Hydrochloride

21 Oct 2026

·saniona.com

Saniona submits IND application for SAN2465 for major depressive disorder

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on neurological and psychiatric disorders, today announces the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for SAN2465 for the treatment of major depressive disorder (MDD). The Phase 1 study is expected to be initiated by the end of 2026, contingent on FDA clearance of the IND application. “The IND submission for SAN2465 represents an important milestone for Saniona and demonstrates our continued focus on execution as we advance our prioritized internal programs into clinical development,” said Pierandrea Muglia, Chief Medical Officer of Saniona. “Our ambition for this compound is to deliver rapid antidepressant efficacy comparable to ketamine and esketamine, without any of the major issues associated with their use, including the acute dissociative and sedative effects that require supervised administration, making treatment impractical and expensive. We look forward to receiving FDA clearance and initiating the Phase 1 study before year-end.” The planned Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of SAN2465 in healthy volunteers. The study will also include validated cognitive tests and established pharmacodynamic measures, such as quantitative EEG, to capture the expected signature of the selective GABA-A α5 negative allosteric modulator at various dose levels, facilitating the definition of the dose range for future clinical studies in patients. Depression affects hundreds of millions of people worldwide [1]. Conventional antidepressants have a delayed onset of several weeks and relatively low remission rates with more than 30% of patients not responding adequately to treatment, leading to treatment-resistant depression [2]. Esketamine (Spravato®), the first approved rapid-acting antidepressant, reached worldwide sales of USD 1.7 billion in 2025 [3], highlighting the significant demand for fast-acting treatment options. However, due to the acute dissociative effect and the risks of sedation, respiratory depression, and abuse liability, esketamine is only available through a restricted Risk Evaluation and Mitigation Strategy (REMS) program requiring administration and monitoring in a certified healthcare setting [4]. SAN2465 is a GABA-A α5 negative allosteric modulator designed to deliver rapid antidepressant effects without the limitations associated with ketamine and esketamine. In the chronic mild stress model, a well-established animal model of depression [5], a single oral dose of SAN2465 produced a rapid and sustained reversal of chronic stress-induced depressive-like symptoms, including anhedonia, anxiety and cognitive impairment. The onset and magnitude of these effects were comparable to ketamine. SAN2465 has also been shown to significantly enhance hippocampal synaptic plasticity, as measured by long-term potentiation (LTP). GABA-A α5 receptors are highly expressed in the hippocampus and related limbic regions involved in emotional regulation, mood and cognition [6,7]. Through selective modulation of these receptors, SAN2465 has the potential to deliver rapid antidepressant efficacy without the dissociative and other adverse effects associated with NMDA receptor antagonists, potentially enabling convenient oral treatment without the need for in-clinic administration and monitoring. [1] World Health Organization. Depression fact sheet, September 2026. https://www-who-int.libproxy1.nus.edu.sg/news-room/fact-sheets/detail/depression [2] Zhdanava M et al. J Clin Psychiatry 2021;82(2):20m13699 [3] Johnson & Johnson. Q4 and full-year 2025 results, January 2026 [4] SPRAVATO® (esketamine) US Prescribing Information, revised March 2026 [5] Willner P. Neurobiol Stress 2017;6:78–93 [6] Sur C et al. Brain Res 1999;822:265–270 [7] Atack JR. Pharmacol Ther 2010;125(1):11–26 The content above comes from the network. if any infringement, please contact us to modify.

INDDrug Approval

21 Oct 2026

·www.biospace.com

Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call

MALVERN, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that it plans to release third quarter 2026 financial and operating results prior to market open on Wednesday, November 4, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at Neuronetics Q3 2026 Earnings . To listen to the conference call on your telephone, participants may register for the call here . While it is not required, it is recommended you join 10 minutes prior to the event start. About Neuronetics Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar® Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (TMS) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO® therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant. 1 The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com . Investor Contact: Mark Klausner ICR Healthcare 443-213-0499 ir@neuronetics.com Media Contact: EvolveMKD 646-517-4220 NeuroStar@evolvemkd.com References 1 The effectiveness of SPRAVATO® in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO®. For more important safety information about SPRAVATO®, please visit spravatohcp.com .

Financial Statement

19 Oct 2026

·www.globenewswire.com

BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group

Partnership with Established Southern California Behavioral Health Provider Aims to Accelerate Innovative Application of Interventional Psychiatry TreatmentsBURLINGTON, Mass. and JERUSALEM, Oct. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced non-invasive neurostimulation treatments for mental health disorders, today announced a strategic collaboration with Inland Psychiatric Medical Group (“IPMG”), an established provider of comprehensive behavioral health services across Southern California. IPMG operates a multidisciplinary behavioral health practice serving patients throughout Southern California, including in Riverside, San Bernardino, Los Angeles, and Orange Counties. Its comprehensive clinical services include psychiatry, medication management, psychotherapy, TMS therapy, esketamine treatment, and clinical research. The collaboration with BrainsWay includes a multisystem order of BrainsWay Deep TMS systems planned for installation at IPMG clinics, and the exploration of a range of scientific, clinical and research projects designed to expand the possibilities of interventional psychiatry and mental health care for the benefit of patients and providers. “We are proud to establish this partnership with IPMG as we explore ways to mutually advance our shared goal of improving patients’ lives through a variety of interventional psychiatry treatments,” said Hadar Levy, Chief Executive Officer of BrainsWay. “This cooperation serves to advance the interests of the patients we serve, and further reflects our strategy of building relationships with key accelerators of innovation in the mental health space.” BrainsWay Deep TMS is an innovative therapy delivered through a patented and unique coil design which is housed within a cushioned, patient and provider-friendly helmet. By pulsing a magnetic field that targets affected structures of the brain, the Deep TMS system is capable of stimulating underactive neural networks. The system is currently FDA-cleared to treat major depressive disorder both with and without anxiety symptoms, obsessive-compulsive disorder (OCD), and smoking addiction. About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com. Forward-Looking StatementThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “targets,” “believes,” “hopes,” “potential” or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. It is important that the reader access the full publication via the link above in order to obtain more detail and context on the findings referenced herein. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure to realize anticipated synergies and other benefits of the proposed transaction; the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission. Contacts: BrainsWay:Ido MaromChief Financial OfficerIdo.Marom@BrainsWay.com Investors:Brian RitchieLifeSci Advisorsbritchie@lifesciadvisors.com

100 Deals associated with Esketamine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D10627	Esketamine Hydrochloride	N01AX14 N06AX27	DB11823

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder	China	Janssen-Cilag International NV	17 Apr 2023
Major depressive disorder, moderate (MDD)	Australia	Janssen-Cilag Pty Ltd.	09 Mar 2021
Depressive Disorder, Major	European Union	Janssen-Cilag International NV	18 Dec 2019
Depressive Disorder, Major	Iceland	Janssen-Cilag International NV	18 Dec 2019
Depressive Disorder, Major	Liechtenstein	Janssen-Cilag International NV	18 Dec 2019
Depressive Disorder, Major	Norway	Janssen-Cilag International NV	18 Dec 2019
Depressive Disorder, Major	United Kingdom	Janssen-Cilag Ltd.	18 Dec 2019
Anesthesia	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	18 Nov 2019
Depressive Disorder, Treatment-Resistant	United States	Janssen Pharmaceuticals, Inc.	05 Mar 2019
Pain	Germany	Pfizer Inc.	01 Aug 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Suicidal Ideation	Phase 3	United States	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Bulgaria	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Estonia	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Germany	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Hungary	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Malaysia	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Slovakia	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	South Africa	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	South Korea	Janssen Research & Development LLC	09 Jun 2017
Suicidal Ideation	Phase 3	Spain	Janssen Research & Development LLC	09 Jun 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05464979 (CTgov)	Early Phase 1	Critical Illness	80	Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato] (Esketamine Intubation Group)	qvhdcxdaao(fomicywkum) = zltlgborqi kkspunmded (zyqffxuoix, 16) View more	-	21 Jul 2026
				Fentanyl+Midazolam (Conventional Intubation Group)	qvhdcxdaao(fomicywkum) = kknckawshm kkspunmded (zyqffxuoix, 20) View more
NCT04425473 (Pubmed \| Pharmacol Res)	Phase 3	Depressive Disorder	435	Esketamine	qrmxabvuuf(zvucfilvpb) = yjrfuhqsju gjvtbeqvuk (emgqkulxmj )	Positive	01 Jul 2026
				Placebo	qrmxabvuuf(zvucfilvpb) = upwjibhdrn gjvtbeqvuk (emgqkulxmj )
NCT04860661 (Pubmed \| Eur J Anaesthesiol)	Not Applicable	Depression, Postpartum	322	Esketamine	fuuayxinde(ccerfpbmci) = Several mild central nervous events, such as dizziness (10.98%), hallucination (10.37%) and dissociation (5.49%), were observed during esketamine treatment. iyjkgmdwkk (hvwymlzvmq ) View more	Positive	01 Jul 2026
				Saline
NCT06062550 (Pubmed \| BMC Anesthesiol)	Phase 4	Pain	312	Esketamine 0.25 mg/ml	ljlzxxkxwb(cfgbcmuwmk) = did not differ among three groups (Esk50 vs. Esk25: mean difference - 2 [95% CI -31 to 28]; Esk75 vs. Esk25: mean difference 13 [95% CI -16 to 43]. rbhicbmeox (lxyyhfpzcd ) View more	Negative	02 Jun 2026
				Esketamine 0.5 mg/ml
DDW2026	Not Applicable	Sedation	858	Esketamine + propofol	vhneqshpvp(czrdsrjdlp): RR = 0.34 (95.0% CI, 0.22 - 0.53), P-Value = 0.34 View more	Positive	02 May 2026
				Placebo + propofol
NCT02493868 (Pubmed \| Int J Psychiatry Clin Pract)	Phase 3	Psychotic Disorders	5,116	Esketamine	ftxzbuulwa(oqdmnqllde) = cbfbmjfiaq ntnahkvtft (hnfhlywcvm )	Negative	12 Feb 2026
				Esketamine	tycfiihwtv(xfhsbbwqxk) = uflezdytqc hfxvefrtzs (qastcmrfmx )
NCT04338321 (ESCAPE-TRD, Pubmed \| Eur Psychiatry)	Phase 3	Depressive Disorder, Treatment-Resistant	676	Esketamine nasal spray	oxyposjggz(hziiioiwqb) = jxobmwlyxl iysfossfcu (axwkrwmmay ) View more	Positive	01 Jan 2026
NCT07034963 (Pubmed \| Drug Des Devel Ther)	Phase 4	-	30	EsketamineRemifentanil + EsketamineRemifentaniline + EsketamineRemifentanil	ffcqlhggul(fqcslybzvi) = self-limiting dizziness (66.7%) sbrxcrjxqh (tfvwsxgbck ) View more	Positive	01 Dec 2025
NCT05715671 (Pubmed \| Sleep Med)	Not Applicable	Dyssomnias	150	Esketamine loading dose 0.15 mg/kg plus maintenance dose 0.15 mg·kg^-1·h^-1	wzhirusoik(xukoujuoye) = significantly higher ujbcweckyc (chkxaudwzk ) View more	Positive	01 Dec 2025
				Esketamine loading dose 0.3 mg/kg plus maintenance dose 0.3 mg·kg^-1·h^-1
NCT06608030 (Pubmed \| Pharmacol Res)	Phase 4	Depressive Disorder \| Anxiety Disorders	142	Esketamine	rqocegehca(xilyqbfkfs) = tnxisyyjbt rldxxxtmgu (mlbvanbipj ) View more	Positive	01 Dec 2025
				Saline	rqocegehca(xilyqbfkfs) = expcgyclok rldxxxtmgu (mlbvanbipj ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis